Hepatitis C Virus

U.S. FDA approves Pegasys and Copegus as hepatitis C treatment for HIV patients

Published in Drug Week, April 1st, 2005

Roche announced that the U.S. Food and Drug Administration (FDA) has approved Pegasys (peginterferon alfa-2a) and Copegus (ribavirin, USP) for the treatment of chronic hepatitis C in patients coinfected with hepatitis C and HIV.

Pegasys combination therapy is the only regimen FDA-approved for hepatitis C treatment in patients with HIV, according to Roche.

Pegasys was approved in 2002 by the FDA for use alone and in combination with Copegus for the treatment of adults with chronic hepatitis C.

"For the first time, the 300,000 Americans who are co-infected with hepatitis C and HIV have an FDA-approved hepatitis C treatment option....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2005-04-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry